Eli Lilly's Triple Agonist Advances to Regulators Following Two Phase 3 Obesity Wins
Eli Lilly's triple agonist drug for obesity is moving towards regulatory submission after successfully completing two additional Phase 3 trials. This development marks a significant step forward in the company's efforts in the competitive obesity treatment market.
Want more?
Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.